Amplifiers

Segra International Announces Development and Validation of In-House Assay for Hop Latent Viroid (HLVd)

Retrieved on: 
Thursday, March 18, 2021

This pathogen assay adds to a substantial list of viral, fungal, and bacterial pathogens Segra already test for in-house as part of their Verified Clean Stock program.

Key Points: 
  • This pathogen assay adds to a substantial list of viral, fungal, and bacterial pathogens Segra already test for in-house as part of their Verified Clean Stock program.
  • Rather than relying on older published HLVd detection assays, Segra's real-time RT-PCR assay is based on consensus of current HLVd sequences recorded in Genbank.
  • "Hop Latent Viroid is an increasingly recognized pathogen now showing obvious economic damage in commercial cannabis cultivation globally.
  • Segra has developed industrial-scale laboratories to produce Verified Clean Stock, robust, and DNA-fingerprinted cannabis plantlets for licensed producers globally.

Oncologica is the First UK Genomic Testing Lab to Be Government Approved for Day 2 and Day 8 Testing

Retrieved on: 
Friday, March 19, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210318005848/en/
    The Oncologica Covid-19 PCR testing and genomic sequencing laboratories.
  • These testing capabilities will expedite the UKs return to work and mitigate the risk of superspreading Covid-19 variants in the population.
  • We are immensely proud of Oncologica achieving government approval as the first UK genomic testing laboratory in the UK to be put on the Governments provider list to undertake day 2 and day 8 Covid-19 PCR testing for travel which is no mean feat.
  • Read more at https://covid19.oncologica.com/coronafocus-day2-day8/
    Oncologica is a world leading precision cancer medicine and Covid-19 testing and genomic sequencing laboratory based in Cambridge, UK.

DGAP-News: XPhyto Therapeutics Corp.: XPhyto announces European Approval for 25 Minute COVID-19 PCR Test

Retrieved on: 
Thursday, March 18, 2021

VANCOUVER, BC / ACCESSWIRE / March 18, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) ("XPhyto" or the "Company"), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"), are pleased to announce the European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system ("Covid-ID Lab").

Key Points: 
  • VANCOUVER, BC / ACCESSWIRE / March 18, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) ("XPhyto" or the "Company"), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"), are pleased to announce the European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system ("Covid-ID Lab").
  • Covid-ID Lab is now registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test.
  • With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic," said Hugh Rogers, CEO and Director of XPhyto.
  • For assay performance, Covid-ID Lab requires only a single 20-minute PCR thermal cycle without prior RNA extraction as part of the sample preparation.

Global Nucleic Acid Amplification Life Science Dashboard 2021

Retrieved on: 
Thursday, March 11, 2021

DUBLIN, March 11, 2021 /PRNewswire/ -- The "2021 Nucleic Acid Amplification Life Science Dashboard Series 5 (NA & EMEA)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 11, 2021 /PRNewswire/ -- The "2021 Nucleic Acid Amplification Life Science Dashboard Series 5 (NA & EMEA)" report has been added to ResearchAndMarkets.com's offering.
  • As life science suppliers continue to improve products and services in the nucleic acid amplification market, nucleic acid amplification kits and reagents represent a significant market within the life sciences industry.
  • The 2021 Nucleic Acid Amplification Dashboard is the fifth in a series that characterizes the dynamic market for products for nucleic acid amplification experiments.
  • The 2021 Nucleic Acid Amplification Dashboard was developed from responses to a 29-question survey completed by 523 scientists located in North America and Europe.

2021 Nucleic Acid Amplification Life Science Dashboard Series 5: North America and EMEA - Market Landscape, Products, Competitors, and Sales & Marketing Strategies - ResearchAndMarkets.com

Retrieved on: 
Monday, March 8, 2021

The "2021 Nucleic Acid Amplification Life Science Dashboard Series 5 (NA & EMEA)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2021 Nucleic Acid Amplification Life Science Dashboard Series 5 (NA & EMEA)" report has been added to ResearchAndMarkets.com's offering.
  • As life science suppliers continue to improve products and services in the nucleic acid amplification market, nucleic acid amplification kits and reagents represent a significant market within the life sciences industry.
  • 2021 Nucleic Acid Amplification Dashboard is the fifth in a series that characterizes the dynamic market for products for nucleic acid amplification experiments.
  • This 2021 Dashboard provides a snapshot of the current market landscape and is compared with data from the 2014 Nucleic Acid Amplification Dashboard where relevant, providing an ongoing story of how the market is adapting to new products, new competitors and new sales and marketing strategies.

Applied DNA to Participate in Upcoming Conferences

Retrieved on: 
Monday, March 8, 2021

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, will be participating in the following virtual investor conferences.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, will be participating in the following virtual investor conferences.
  • The panel is scheduled for March 15, 2021 at 12:00pm ET and will be available to all Conference attendees, as well as on Applied DNAs website ( link ).
  • Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping, and pre-clinical nucleic acid-based therapeutic drug candidates.
  • Applied DNA is a member of the Russell Microcap Index.

Abbott Receives FDA EUA for Laboratory PCR Assay That Detects and Differentiates SARS-CoV-2, Flu A, Flu B and RSV in One Test - and FDA EUA for Asymptomatic Usage of Alinity m COVID-19 Test

Retrieved on: 
Friday, March 5, 2021

Test will run on Abbott's Alinity m system the company's most advanced high-volume laboratory molecular instrument.

Key Points: 
  • Test will run on Abbott's Alinity m system the company's most advanced high-volume laboratory molecular instrument.
  • Alinity m uses Polymerase Chain Reaction (PCR) technology, which is known for its high sensitivity in detecting infectious diseases.
  • To help fight the pandemic, Abbott has accelerated placements of the Alinity m system in hospital labs, academic centers and labs that are critical to patient care.
  • The updated Alinity m SARS-CoV-2 test, Alinity m Resp-4-Plex assay, and Abbott's existing testing technologies willnow allbe available to support front-line healthcare workers.

Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya

Retrieved on: 
Thursday, March 4, 2021

CA Medlynks Kenya, Ltd., in collaboration with the government of Meru County in Kenya, will support the setup of PCR testing laboratories, along with procurement of equipment necessary for testing and training of screening technicians.

Key Points: 
  • CA Medlynks Kenya, Ltd., in collaboration with the government of Meru County in Kenya, will support the setup of PCR testing laboratories, along with procurement of equipment necessary for testing and training of screening technicians.
  • Meru County, one of Kenya's 47 counties, is the most populous county in the Eastern Province of Kenya with approximately 1.35 million people.
  • Through this support, including the new support for Connect Afya, Eisai will continue in its contribution to mitigating the spread of the novel coronavirus infection in Kenya and other African countries.
  • As of February 2021, the startup has supplied diagnostic services and in-vitro diagnostic medical equipment, including novel coronavirus infection reverse transcription PCR screening equipment, to over thirty healthcare organizations, clinics, and corporations across Kenya.

Co-Diagnostics New Rapid PCR Point-of-Care and at Home Testing Platform to Detect Covid-19 and Other Diseases Using CoPrimer™ Technology

Retrieved on: 
Tuesday, March 2, 2021

The platform chemistry was created by Co-Diagnostics utilizing proprietary CoPrimer technology, Direct Saliva extraction-free protocols, and freeze-dried reagents.

Key Points: 
  • The platform chemistry was created by Co-Diagnostics utilizing proprietary CoPrimer technology, Direct Saliva extraction-free protocols, and freeze-dried reagents.
  • With this platform, Co-Diagnostics plans to revolutionize the availability of accurate, fast and economical PCR tests as regular Covid-19 testing becomes part of the long-term protocol for many organizations.
  • The rapid gold-standard PCR results from this testing platform would be differentiated from less accurate antigen tests.
  • In addition, PCR may even detect the presence of genetic material of the SARS-CoV-2 virus being carried by vaccinated patients.

Sunquest Lauded by Frost & Sullivan for Driving Efficiency and Compliance with Its Differentiated Molecular Laboratory Information Management System

Retrieved on: 
Tuesday, March 2, 2021

Sunquest's comprehensive portfolio of products and services improves operational efficiency, enhances patient care, and lowers healthcare organizations' costs across the spectrum.

Key Points: 
  • Sunquest's comprehensive portfolio of products and services improves operational efficiency, enhances patient care, and lowers healthcare organizations' costs across the spectrum.
  • Sunquest Mitogen supports multiple molecular workflows such as polymerase chain reaction (PCR), reverse transcription-polymerase chain reaction (RT-PCR), next-generation sequencing (NGS), chromosomal microarray (CMA), and mass spectrometry.
  • While other existing LIMS products are compatible with only about two workflows, Sunquest Mitogen supports more than 10 workflows.
  • "Sunquest strategically leverages its sister company, Data Innovations, vast collection of instrument drivers to makeSunquest Mitogen LIMS instrument-agnostic.